Ying-Hao Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying-Hao Shen has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Chenhao Zhou
Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China
31 shared publications - Minghao Xu
Department of Hepatobiliary Surgery and Liver Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
31 shared publications - Ning Ren
Fudan University
31 shared publications - Dongmei Gao
Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
29 shared publications - Fu Wang
Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
29 shared publications - Jia-Lei Sun
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P. R. China
29 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (7) , 102208
CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma
- 2 July 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (7) , 102208
Open AccessCLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma
- Open Access
- 2 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.
- 2 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
Open AccessThe MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.
- Open Access
- 2 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011648
FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
Background: The efficacy of immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) is limited by heterogeneity in individual responses to therapy. The heterogeneous phenotypes and crucial roles of cancer-associated fibroblasts (CAFs) in immunotherapy resistance remain largely unclear. Methods: A specific CAF subset was identified by integrating comprehensive single-cell RNA sequencing, spatial transcriptomics and transcriptome profiling of patients with HCC with different responses to antiprogrammed cell death protein 1 (anti-PD-1) therapy. Mouse orthotopic HCC models and a coculture system were constructed, and cytometry by time-of-flight analysis was performed to investigate the functions and mechanisms of specific CAFs in the immune context of HCC. Results: We identified a distinct flavin-containing monooxygenase 2 (FMO2)+ CAF subset associated with a favorable response to anti-PD-1 therapy and better clinical outcomes. FMO2+ CAFs increase anti-PD-1 treatment efficacy by promoting tertiary lymphoid structure formation and increasing the infiltration of CD8+ T cells and M1-like macrophages through the C-C motif chemokine ligand 19 (CCL19)-C-C motif chemokine receptor 7 axis. Mechanistically, FMO2 promotes nuclear factor kappa B/p65-mediated CCL19 expression by competitively binding to glycogen synthase 1 (GYS1) with praja ring finger ubiquitin ligase 1 (PJA1), thereby suppressing the PJA1-mediated proteasomal degradation of GYS1. CCL19 treatment potentiated the therapeutic efficacy of anti-PD-1 therapy in mouse orthotopic HCC models. A favorable immunotherapy response was observed in patients with HCC with high serum levels of CCL19. Conclusions: We identified a novel FMO2+ CAF subset that serves as a critical regulator of microenvironmental immune properties and a predictive biomarker of the immunotherapy response in patients with HCC. CCL19 in combination with anti-PD-1 therapy may constitute a novel therapeutic strategy for HCC.
- 2 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011648
Open AccessFMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
Background: The efficacy of immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) is limited by heterogeneity in individual responses to therapy. The heterogeneous phenotypes and crucial roles of cancer-associated fibroblasts (CAFs) in immunotherapy resistance remain largely unclear. Methods: A specific CAF subset was identified by integrating comprehensive single-cell RNA sequencing, spatial transcriptomics and transcriptome profiling of patients with HCC with different responses to antiprogrammed cell death protein 1 (anti-PD-1) therapy. Mouse orthotopic HCC models and a coculture system were constructed, and cytometry by time-of-flight analysis was performed to investigate the functions and mechanisms of specific CAFs in the immune context of HCC. Results: We identified a distinct flavin-containing monooxygenase 2 (FMO2)+ CAF subset associated with a favorable response to anti-PD-1 therapy and better clinical outcomes. FMO2+ CAFs increase anti-PD-1 treatment efficacy by promoting tertiary lymphoid structure formation and increasing the infiltration of CD8+ T cells and M1-like macrophages through the C-C motif chemokine ligand 19 (CCL19)-C-C motif chemokine receptor 7 axis. Mechanistically, FMO2 promotes nuclear factor kappa B/p65-mediated CCL19 expression by competitively binding to glycogen synthase 1 (GYS1) with praja ring finger ubiquitin ligase 1 (PJA1), thereby suppressing the PJA1-mediated proteasomal degradation of GYS1. CCL19 treatment potentiated the therapeutic efficacy of anti-PD-1 therapy in mouse orthotopic HCC models. A favorable immunotherapy response was observed in patients with HCC with high serum levels of CCL19. Conclusions: We identified a novel FMO2+ CAF subset that serves as a critical regulator of microenvironmental immune properties and a predictive biomarker of the immunotherapy response in patients with HCC. CCL19 in combination with anti-PD-1 therapy may constitute a novel therapeutic strategy for HCC.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Representative IHC staining images showing the expressions of SLAMF7 and CCL2 in HCC samples. Scale bar: 200 μm (left) and 20 μm (right). (B) The prognostic prediction performances of SLAMF7 in combination with CCL2 for OS and DFS in our Fudan LCI HCC cohort.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Representative IHC staining images showing the expressions of SLAMF7 and CCL2 in HCC samples. Scale bar: 200 μm (left) and 20 μm (right). (B) The prognostic prediction performances of SLAMF7 in combination with CCL2 for OS and DFS in our Fudan LCI HCC cohort.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Top: Schematic showing the administration schedule of clophosome in the indicated orthotopic HCC mouse models. Bottom: Gross appearance of the liver bearing Hepa1-6 tumors in the indicated treatment groups. (B) The tumor weight and tumor volume of each group at the study endpoint (5 mice per group). NS, not significant, **P<0.01, and ***P<0.001, one-way ANOVA with a post hoc LSD test.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Top: Schematic showing the administration schedule of clophosome in the indicated orthotopic HCC mouse models. Bottom: Gross appearance of the liver bearing Hepa1-6 tumors in the indicated treatment groups. (B) The tumor weight and tumor volume of each group at the study endpoint (5 mice per group). NS, not significant, **P<0.01, and ***P<0.001, one-way ANOVA with a post hoc LSD test.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
Supplementary materials and methods
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
Supplementary materials and methods
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Immunoblot assays showing the phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (B) Flow cytometry analyses of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells. (C) Chemotaxis assays showing the effect of supernatants from the indicated coculture systems on the migration abilities of THP-1-differentiated macrophages. Scale bar: 100 μm. (D) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (E) Immunoblot assays of phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (F) ChIP-qPCR analyses of ATF2 binding to the CCL2 gene promoter in HCC cell lines with SLAMF7 overexpression and knockdown. (G) Immunoblot assays of SLAMF7, and ATF2 protein levels in the indicated HCC cells. **P<0.01, and ***P<0.001, Student’s t test. Experiments were repeated three time and results were present as the mean ± SD.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Immunoblot assays showing the phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (B) Flow cytometry analyses of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells. (C) Chemotaxis assays showing the effect of supernatants from the indicated coculture systems on the migration abilities of THP-1-differentiated macrophages. Scale bar: 100 μm. (D) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (E) Immunoblot assays of phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (F) ChIP-qPCR analyses of ATF2 binding to the CCL2 gene promoter in HCC cell lines with SLAMF7 overexpression and knockdown. (G) Immunoblot assays of SLAMF7, and ATF2 protein levels in the indicated HCC cells. **P<0.01, and ***P<0.001, Student’s t test. Experiments were repeated three time and results were present as the mean ± SD.